SG11201900383RA - Pseudo-viral particles and uses of same - Google Patents

Pseudo-viral particles and uses of same

Info

Publication number
SG11201900383RA
SG11201900383RA SG11201900383RA SG11201900383RA SG11201900383RA SG 11201900383R A SG11201900383R A SG 11201900383RA SG 11201900383R A SG11201900383R A SG 11201900383RA SG 11201900383R A SG11201900383R A SG 11201900383RA SG 11201900383R A SG11201900383R A SG 11201900383RA
Authority
SG
Singapore
Prior art keywords
same
pseudo
viral particles
particles
fusion protein
Prior art date
Application number
SG11201900383RA
Other languages
English (en)
Inventor
Véronique Gomord
Louis-Philippe Vezina
Loïc Faye
Virginie Catala
Anne-Catherine Fitchette
Original Assignee
Angany Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angany Inc filed Critical Angany Inc
Publication of SG11201900383RA publication Critical patent/SG11201900383RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201900383RA 2016-07-29 2017-07-28 Pseudo-viral particles and uses of same SG11201900383RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1657424A FR3054547B1 (fr) 2016-07-29 2016-07-29 Particules pseudo-virales et leurs utilisations
PCT/FR2017/052146 WO2018020195A1 (fr) 2016-07-29 2017-07-28 Particules pseudo-virales et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201900383RA true SG11201900383RA (en) 2019-02-27

Family

ID=57045182

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900383RA SG11201900383RA (en) 2016-07-29 2017-07-28 Pseudo-viral particles and uses of same

Country Status (10)

Country Link
US (1) US20190160167A1 (fr)
EP (1) EP3490597A1 (fr)
JP (2) JP7461742B2 (fr)
KR (1) KR20190038600A (fr)
AU (1) AU2017303820B2 (fr)
BR (1) BR112019001779A2 (fr)
CA (1) CA3031294A1 (fr)
FR (1) FR3054547B1 (fr)
SG (1) SG11201900383RA (fr)
WO (1) WO2018020195A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246041A2 (fr) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions et procédés pour un affichage de surface multivalent sur des particules enveloppées
CN117813106A (zh) * 2021-05-20 2024-04-02 阿奇洛伊斯生物制药公司 免疫检查点多价颗粒组合物和使用方法
WO2023183136A1 (fr) * 2022-03-11 2023-09-28 National Health Research Institutes Composition comprenant un antigène et de l'adn et utilisation associée
WO2023215699A1 (fr) * 2022-05-04 2023-11-09 Achelois Biopharma, Inc. Affichage multivalent sur des particules enveloppées avec des domaines d'oligomérisation humains

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1255510A (fr) 1960-01-28 1961-03-10 S E B A M Charnière invisible pour porte de meuble
US7767212B2 (en) * 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP2044224A4 (fr) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc Particules de type virus chimérique
CA2669455A1 (fr) 2006-11-08 2008-05-15 Centre National De La Recherche Scientifique-Cnrs Ensemble de sequences pour ciblage d'expression et controle des modifications post-traduction d'un polypeptide de recombinaison
MX2010007962A (es) * 2007-11-27 2010-11-10 Medicago Inc Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina.
US20120052082A1 (en) * 2010-04-09 2012-03-01 Zetra Biologicals, LLC Cross-protective influenza vaccine
TWI620816B (zh) * 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
FR2991996B1 (fr) * 2012-06-13 2016-07-08 Angany Genetics Methode de production d'allergenes recombinants de haute qualite par expression transitoire chez nicotiana benthamiana
WO2014070848A1 (fr) * 2012-11-05 2014-05-08 Georgia State University Research Foundation Vaccin universel contre la grippe à base de protéines m2e multiples hétérologues
EP2978848B1 (fr) 2013-03-28 2020-05-06 Medicago Inc. Production de particules de type viral de la grippe dans des plantes

Also Published As

Publication number Publication date
EP3490597A1 (fr) 2019-06-05
FR3054547A1 (fr) 2018-02-02
US20190160167A1 (en) 2019-05-30
AU2017303820B2 (en) 2022-10-20
JP7461742B2 (ja) 2024-04-04
CA3031294A1 (fr) 2018-02-01
WO2018020195A1 (fr) 2018-02-01
JP2019531760A (ja) 2019-11-07
AU2017303820A1 (en) 2019-02-07
KR20190038600A (ko) 2019-04-08
BR112019001779A2 (pt) 2019-05-07
FR3054547B1 (fr) 2020-06-05
JP2024028887A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
SG11201900383RA (en) Pseudo-viral particles and uses of same
AU2015261536B2 (en) Improved immunoglobulin variable domains
MX2019011952A (es) Proteina anti-garp y sus usos.
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
WO2013184939A3 (fr) Polypeptides hybrides comprenant une protéine active liée à un polypeptide à domaine mucin
EP4286400A3 (fr) Agents pharmaceutiques peptidiques améliorés
EP3971286A3 (fr) Lentivirus pseudotypés avec l'enveloppe du virus nipah et procédés d'utilisation
EP2542581A4 (fr) Anticorps spécifique d'apolipoprotéine, et procédés d'utilisation correspondant
WO2011056899A3 (fr) Particules de type viral (vlp) chimériques à base de gag de polypeptide rsv-f et de lentivirus ou alpharétrovirus
WO2015112558A3 (fr) Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
WO2012010974A3 (fr) Compositions pharmaceutiques combinées et procédé de traitement du vertige, de la cinétose et de la dystonie végétative vasculaire
EP3186272A4 (fr) Protéines membranaires stabilisées au moyen de peptides fonctionnalisés organisés en feuillets bêta, constructions les comprenant et procédés de formation et d'utilisation les utilisant
SG10201907901XA (en) Antibodies, uses & methods
SG10201807572PA (en) Robust antibody purification
PH12016501689A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP3976642A4 (fr) Anticorps apoe, protéines de fusion et leurs utilisations
WO2018067582A3 (fr) Immunogènes de peptides de fusion env du vih-1 et leur utilisation
MX2020005530A (es) Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas.
NZ731491A (en) Cd83 binding proteins and uses thereof
EP3257523A4 (fr) Utilisation de complexe polypeptidique en tant que vecteur de médicament polypeptidique ou protéique, procédé, et complexe de protéine hybride correspondant
MX2018003445A (es) Expresion de proteinas que contienen fc.
EP2816355B8 (fr) Procédé de détection de bactéries, procédé de fabrication de protéines de fusion et protéine de fusion
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
EP3636278A3 (fr) Composition immunogène contre le clostridium difficile